The American Society of Clinical Oncology (ASCO) has announced that the following guideline, "Management of Immune-related Adverse Effects: ASCO Guideline Protocol" is now open for public comment. This latest guideline incorporates new evidence to ensure the most current recommendations are provided.
As part of ASCO's development process, they invite reviews and feedback for a 2- to 3-week period. Interested parties are encouraged to submit their comments here by Wednesday, March 19, 2025 at 11:59 PM EST. Your input is valuable in shaping the future of cancer management.
Copyright © 2025 Guideline Central, All Rights Reserved.